Edward Nash
Stock Analyst at Canaccord Genuity
(3.64)
# 838
Out of 4,650 analysts
69
Total ratings
46.67%
Success rate
8.38%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Nash
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TVTX Travere Therapeutics | Maintains: Buy | $23 → $22 | $18.37 | +19.76% | 8 | Sep 30, 2024 | |
| VTYX Ventyx Biosciences | Maintains: Buy | $15 → $14 | $2.39 | +485.77% | 6 | Aug 12, 2024 | |
| CORT Corcept Therapeutics | Maintains: Buy | $38 → $78 | $48.21 | +61.79% | 5 | Jul 31, 2024 | |
| VRNA Verona Pharma | Maintains: Buy | $35 → $37 | $33.67 | +9.89% | 7 | Jul 22, 2024 | |
| CRDL Cardiol Therapeutics | Maintains: Buy | $6 → $8 | $1.83 | +337.16% | 3 | May 23, 2024 | |
| AKRO Akero Therapeutics | Maintains: Buy | $59 → $56 | $31.73 | +76.49% | 5 | May 13, 2024 | |
| IVA Inventiva | Maintains: Buy | $12 → $20 | $2.68 | +646.27% | 2 | Apr 8, 2024 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $21 → $9 | $2.34 | +284.62% | 1 | Mar 27, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $338 → $377 | $217.79 | +73.10% | 8 | Mar 15, 2024 | |
| THTX Theratechnologies | Assumes: Hold | $8 | $1.23 | +550.67% | 4 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $17 | $5.68 | +199.30% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $14.72 | +226.09% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $3 → $2 | $2.29 | -12.66% | 4 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $900 → $180 | $3.66 | +4,818.03% | 2 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $82 | $52.80 | +55.30% | 6 | Jun 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $120 → $80 | $7.76 | +930.93% | 3 | Sep 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $6.42 | +647.66% | 1 | May 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $650 | $6.57 | +9,793.46% | 1 | Nov 8, 2017 |
Travere Therapeutics
Sep 30, 2024
Maintains: Buy
Price Target: $23 → $22
Current: $18.37
Upside: +19.76%
Ventyx Biosciences
Aug 12, 2024
Maintains: Buy
Price Target: $15 → $14
Current: $2.39
Upside: +485.77%
Corcept Therapeutics
Jul 31, 2024
Maintains: Buy
Price Target: $38 → $78
Current: $48.21
Upside: +61.79%
Verona Pharma
Jul 22, 2024
Maintains: Buy
Price Target: $35 → $37
Current: $33.67
Upside: +9.89%
Cardiol Therapeutics
May 23, 2024
Maintains: Buy
Price Target: $6 → $8
Current: $1.83
Upside: +337.16%
Akero Therapeutics
May 13, 2024
Maintains: Buy
Price Target: $59 → $56
Current: $31.73
Upside: +76.49%
Inventiva
Apr 8, 2024
Maintains: Buy
Price Target: $12 → $20
Current: $2.68
Upside: +646.27%
Rani Therapeutics Holdings
Mar 27, 2024
Maintains: Buy
Price Target: $21 → $9
Current: $2.34
Upside: +284.62%
Madrigal Pharmaceuticals
Mar 15, 2024
Maintains: Buy
Price Target: $338 → $377
Current: $217.79
Upside: +73.10%
Theratechnologies
Jul 3, 2023
Assumes: Hold
Price Target: $8
Current: $1.23
Upside: +550.67%
May 19, 2023
Maintains: Buy
Price Target: $16 → $17
Current: $5.68
Upside: +199.30%
May 18, 2023
Initiates: Buy
Price Target: $48
Current: $14.72
Upside: +226.09%
May 17, 2023
Maintains: Hold
Price Target: $3 → $2
Current: $2.29
Upside: -12.66%
Aug 8, 2022
Downgrades: Hold
Price Target: $900 → $180
Current: $3.66
Upside: +4,818.03%
Jun 19, 2020
Maintains: Buy
Price Target: $80 → $82
Current: $52.80
Upside: +55.30%
Sep 13, 2019
Maintains: Hold
Price Target: $120 → $80
Current: $7.76
Upside: +930.93%
May 24, 2018
Initiates: Buy
Price Target: $48
Current: $6.42
Upside: +647.66%
Nov 8, 2017
Initiates: Buy
Price Target: $650
Current: $6.57
Upside: +9,793.46%